StockNews.AI
SEER
StockNews.AI
187 days

Seer to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

1. Seer will report Q4 and full-year 2024 results on February 27, 2025. 2. A conference call will be hosted on the same day at 1:30 p.m. PT. 3. Seer's Proteograph Product Suite offers innovative proteomic analysis solutions. 4. The product suite facilitates deep, unbiased analysis in hours. 5. Seer's solutions are designed for integration into existing lab setups.

Earnings
0%Current Return
VS
0%S&P 500
$2.3102/13 04:20 PM EDTEvent Start
$2.3102/14 10:28 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Bullish?

Upcoming financial results could showcase revenue growth potential. Previous earnings reports have positively influenced stock price.

How important is it?

Financial results can significantly impact investor confidence and stock performance. Seer's innovative approach may drive increased interest.

Why Short Term?

Financial results will impact market sentiment in the near term. The stock may react quickly post-announcement.

Related Companies

SEERNASDAQ
February 13, 2025 16:15 ET  | Source: Seer, Inc. REDWOOD CITY, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the fourth quarter and full year 2024 on Thursday, February 27, 2025. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the event. About SeerSeer is a life sciences company developing transformative products that open a new gateway to the proteome. Seer’s Proteograph™ Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio. Media Contact:Patrick Schmidtpr@seer.bio  Investor Contact:Carrie Mendivilinvestor@seer.bio 

Related News